Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough.

[1]  W. Mackillop,et al.  Estimating the optimal perioperative chemotherapy utilization rate for muscle‐invasive bladder cancer , 2019, Cancer medicine.

[2]  A. Zlotta,et al.  Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions? , 2019, PloS one.

[3]  R. Bristow,et al.  Neoadjuvant Chemotherapy Before Bladder‐Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.

[4]  G. Pond,et al.  Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.

[5]  W. Mackillop,et al.  Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  W. Mackillop,et al.  Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? , 2017, Urologic oncology.

[7]  A. Niemierko,et al.  Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.

[8]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.